Nebulizable archaeolipid nanovesicles for drug delivery to the lungs

Autores
Altube, María Julia
Año de publicación
2020
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
To improve safety and efficacy in the treatment of lungdiseases like asthma and lung infection, medications areroutinely inhaled rather than administered systemically.Inhaled medication can achieve the same effectiveconcentration in lungs at doses lower than by oral orintravenous routes. Moreover, the efficacy of inhaledmedication can be enhanced by performing targeted deliveryto selected body sites, with tailored nanoparticulate carriers.Inhaled nanoparticles preferentially accumulate in lungs, thuslimiting drugs penetration into the bloodstream, consequentlydecreasing adverse systemic side effects. Inhalednanoparticulate medication, however, needs to overcomesome critical drawbacks. Firstly, nanoparticles must towithstand the physical stress produced by the nebulizerforces, and to surpass the barriers imposed by the lungmorphology. Secondly, nanoparticles must avoid the trappinginto the mucociliar escalator, being free to cross thesurfactant layer covering the alveolar epithelium. Thirdly,safety issues related with lung epithelium integrity must beevaluated. This presentation will describe the performance ofnebulizable nanovesicles, as delivery systems for antibiotics oranti-inflammatory drugs to the lungs, on in vitro models ofmucus and surfactant layers and of inflamed alveolarepithelium in an air-liquid interface. The advantages of thesenovel nebulizable nanovesicles made of archaeolipidsextracted from the cellular membrane of archaebacterias willbe analyzed in comparison with conventional inhaledliposomes.
Fil: Altube, María Julia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Biología
Sociedad Argentina de Protozoología
Asociación Argentina de Nanomedicinas
Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
Materia
Nanomedicine
Inhalatory
Nebulization
Lung model
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/263793
Acceder
id CONICETDig_2ae5ec1f00290276b0141b6d8f9faa08
oai_identifier_str oai:ri.conicet.gov.ar:11336/263793
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Nebulizable archaeolipid nanovesicles for drug delivery to the lungsAltube, María JuliaNanomedicineInhalatoryNebulizationLung modelhttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2To improve safety and efficacy in the treatment of lungdiseases like asthma and lung infection, medications areroutinely inhaled rather than administered systemically.Inhaled medication can achieve the same effectiveconcentration in lungs at doses lower than by oral orintravenous routes. Moreover, the efficacy of inhaledmedication can be enhanced by performing targeted deliveryto selected body sites, with tailored nanoparticulate carriers.Inhaled nanoparticles preferentially accumulate in lungs, thuslimiting drugs penetration into the bloodstream, consequentlydecreasing adverse systemic side effects. Inhalednanoparticulate medication, however, needs to overcomesome critical drawbacks. Firstly, nanoparticles must towithstand the physical stress produced by the nebulizerforces, and to surpass the barriers imposed by the lungmorphology. Secondly, nanoparticles must avoid the trappinginto the mucociliar escalator, being free to cross thesurfactant layer covering the alveolar epithelium. Thirdly,safety issues related with lung epithelium integrity must beevaluated. This presentation will describe the performance ofnebulizable nanovesicles, as delivery systems for antibiotics oranti-inflammatory drugs to the lungs, on in vitro models ofmucus and surfactant layers and of inflamed alveolarepithelium in an air-liquid interface. The advantages of thesenovel nebulizable nanovesicles made of archaeolipidsextracted from the cellular membrane of archaebacterias willbe analyzed in comparison with conventional inhaledliposomes.Fil: Altube, María Julia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaLXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de LaboratorioMar del PlataArgentinaSociedad Argentina de Investigación ClínicaAsociación Argentina de Farmacología ExperimentalSociedad Argentina de BiologíaSociedad Argentina de ProtozoologíaAsociación Argentina de NanomedicinasAsociación Argentina de Ciencia y Tecnología de Animales de LaboratorioFundación Revista Medicina2020info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/263793Nebulizable archaeolipid nanovesicles for drug delivery to the lungs; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio; Mar del Plata; Argentina; 2019; 49-491669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com/indices-de-2010-a-2019/tapa-vol-79-ano-2019-s4/Internacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:23:11Zoai:ri.conicet.gov.ar:11336/263793instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:23:11.811CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Nebulizable archaeolipid nanovesicles for drug delivery to the lungs
title Nebulizable archaeolipid nanovesicles for drug delivery to the lungs
spellingShingle Nebulizable archaeolipid nanovesicles for drug delivery to the lungs
Altube, María Julia
Nanomedicine
Inhalatory
Nebulization
Lung model
title_short Nebulizable archaeolipid nanovesicles for drug delivery to the lungs
title_full Nebulizable archaeolipid nanovesicles for drug delivery to the lungs
title_fullStr Nebulizable archaeolipid nanovesicles for drug delivery to the lungs
title_full_unstemmed Nebulizable archaeolipid nanovesicles for drug delivery to the lungs
title_sort Nebulizable archaeolipid nanovesicles for drug delivery to the lungs
dc.creator.none.fl_str_mv Altube, María Julia
author Altube, María Julia
author_facet Altube, María Julia
author_role author
dc.subject.none.fl_str_mv Nanomedicine
Inhalatory
Nebulization
Lung model
topic Nanomedicine
Inhalatory
Nebulization
Lung model
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv To improve safety and efficacy in the treatment of lungdiseases like asthma and lung infection, medications areroutinely inhaled rather than administered systemically.Inhaled medication can achieve the same effectiveconcentration in lungs at doses lower than by oral orintravenous routes. Moreover, the efficacy of inhaledmedication can be enhanced by performing targeted deliveryto selected body sites, with tailored nanoparticulate carriers.Inhaled nanoparticles preferentially accumulate in lungs, thuslimiting drugs penetration into the bloodstream, consequentlydecreasing adverse systemic side effects. Inhalednanoparticulate medication, however, needs to overcomesome critical drawbacks. Firstly, nanoparticles must towithstand the physical stress produced by the nebulizerforces, and to surpass the barriers imposed by the lungmorphology. Secondly, nanoparticles must avoid the trappinginto the mucociliar escalator, being free to cross thesurfactant layer covering the alveolar epithelium. Thirdly,safety issues related with lung epithelium integrity must beevaluated. This presentation will describe the performance ofnebulizable nanovesicles, as delivery systems for antibiotics oranti-inflammatory drugs to the lungs, on in vitro models ofmucus and surfactant layers and of inflamed alveolarepithelium in an air-liquid interface. The advantages of thesenovel nebulizable nanovesicles made of archaeolipidsextracted from the cellular membrane of archaebacterias willbe analyzed in comparison with conventional inhaledliposomes.
Fil: Altube, María Julia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Biología
Sociedad Argentina de Protozoología
Asociación Argentina de Nanomedicinas
Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
description To improve safety and efficacy in the treatment of lungdiseases like asthma and lung infection, medications areroutinely inhaled rather than administered systemically.Inhaled medication can achieve the same effectiveconcentration in lungs at doses lower than by oral orintravenous routes. Moreover, the efficacy of inhaledmedication can be enhanced by performing targeted deliveryto selected body sites, with tailored nanoparticulate carriers.Inhaled nanoparticles preferentially accumulate in lungs, thuslimiting drugs penetration into the bloodstream, consequentlydecreasing adverse systemic side effects. Inhalednanoparticulate medication, however, needs to overcomesome critical drawbacks. Firstly, nanoparticles must towithstand the physical stress produced by the nebulizerforces, and to surpass the barriers imposed by the lungmorphology. Secondly, nanoparticles must avoid the trappinginto the mucociliar escalator, being free to cross thesurfactant layer covering the alveolar epithelium. Thirdly,safety issues related with lung epithelium integrity must beevaluated. This presentation will describe the performance ofnebulizable nanovesicles, as delivery systems for antibiotics oranti-inflammatory drugs to the lungs, on in vitro models ofmucus and surfactant layers and of inflamed alveolarepithelium in an air-liquid interface. The advantages of thesenovel nebulizable nanovesicles made of archaeolipidsextracted from the cellular membrane of archaebacterias willbe analyzed in comparison with conventional inhaledliposomes.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/263793
Nebulizable archaeolipid nanovesicles for drug delivery to the lungs; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio; Mar del Plata; Argentina; 2019; 49-49
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/263793
identifier_str_mv Nebulizable archaeolipid nanovesicles for drug delivery to the lungs; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas y VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio; Mar del Plata; Argentina; 2019; 49-49
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com/indices-de-2010-a-2019/tapa-vol-79-ano-2019-s4/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Internacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846082638254702592
score 13.22299

Publicaciones similares